These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 9808609)

  • 41. Hepatic lipase deficiency.
    Connelly PW; Hegele RA
    Crit Rev Clin Lab Sci; 1998 Dec; 35(6):547-72. PubMed ID: 9885775
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Variation at position 162 of peroxisome proliferator-activated receptor alpha does not influence the effect of fibrates on cholesterol or triacylglycerol concentrations in hyperlipidaemic subjects.
    Puckey LH; Knight BL
    Pharmacogenetics; 2001 Oct; 11(7):619-24. PubMed ID: 11668221
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
    Julve J; Escolà-Gil JC; Rotllan N; Fiévet C; Vallez E; de la Torre C; Ribas V; Sloan JH; Blanco-Vaca F
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression.
    Post SM; Duez H; Gervois PP; Staels B; Kuipers F; Princen HM
    Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1840-5. PubMed ID: 11701475
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Update on the use of fibrates: focus on bezafibrate.
    Goldenberg I; Benderly M; Goldbourt U
    Vasc Health Risk Manag; 2008; 4(1):131-41. PubMed ID: 18629356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [New concepts on the mechanism of action of fibrates and therapeutic prospectives in atherosclerosis].
    Fruchart JC; Staels B; Duriez P
    Bull Acad Natl Med; 2001; 185(1):63-74; discussion 74-5. PubMed ID: 11474570
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of fibrate treatment in dyslipidemia: an overview.
    Katsiki N; Nikolic D; Montalto G; Banach M; Mikhailidis DP; Rizzo M
    Curr Pharm Des; 2013; 19(17):3124-31. PubMed ID: 23317397
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
    Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
    Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PPARs: transcription factors controlling lipid and lipoprotein metabolism.
    Bocher V; Pineda-Torra I; Fruchart JC; Staels B
    Ann N Y Acad Sci; 2002 Jun; 967():7-18. PubMed ID: 12079830
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha.
    Kockx M; Gervois PP; Poulain P; Derudas B; Peters JM; Gonzalez FJ; Princen HM; Kooistra T; Staels B
    Blood; 1999 May; 93(9):2991-8. PubMed ID: 10216095
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host.
    Khovidhunkit W; Kim MS; Memon RA; Shigenaga JK; Moser AH; Feingold KR; Grunfeld C
    J Lipid Res; 2004 Jul; 45(7):1169-96. PubMed ID: 15102878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control].
    Bocher V; Chinetti G; Fruchart JC; Staels B
    J Soc Biol; 2002; 196(1):47-52. PubMed ID: 12134632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver.
    Roglans N; Bellido A; Rodríguez C; Cabrero A; Novell F; Ros E; Zambón D; Laguna JC
    Clin Pharmacol Ther; 2002 Dec; 72(6):692-701. PubMed ID: 12496750
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice.
    Peters JM; Hennuyer N; Staels B; Fruchart JC; Fievet C; Gonzalez FJ; Auwerx J
    J Biol Chem; 1997 Oct; 272(43):27307-12. PubMed ID: 9341179
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
    Farnier M; Salko T; Isaacsohn JL; Troendle AJ; Dejager S; Gonasun L
    Am J Cardiol; 2003 Oct; 92(7):794-7. PubMed ID: 14516878
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.
    Kockx M; Princen HM; Kooistra T
    Thromb Haemost; 1998 Dec; 80(6):942-8. PubMed ID: 9869165
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.
    Brisson D; Ledoux K; Bossé Y; St-Pierre J; Julien P; Perron P; Hudson TJ; Vohl MC; Gaudet D
    Pharmacogenetics; 2002 Jun; 12(4):313-20. PubMed ID: 12042669
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PPAR: a mediator of peroxisome proliferator action.
    Green S
    Mutat Res; 1995 Dec; 333(1-2):101-9. PubMed ID: 8538617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins.
    Huang Y; Liu XQ; Rall SC; Mahley RW
    J Biol Chem; 1998 Jul; 273(28):17483-90. PubMed ID: 9651338
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis.
    Neve BP; Fruchart JC; Staels B
    Biochem Pharmacol; 2000 Oct; 60(8):1245-50. PubMed ID: 11007963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.